Ironwood Pharmaceuticals, Inc. Class A
(NASDAQ : IRWD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
-1.84%24.2714.1%$215.51m
SHPGShire PLC Sponsored ADR
-0.34%161.850.4%$146.66m
JAZZJazz Pharmaceuticals Plc
-0.91%178.502.2%$132.60m
SAGESAGE Therapeutics, Inc.
-4.83%153.469.6%$122.44m
ENDPEndo International Plc
1.94%9.488.9%$88.71m
PRGOPerrigo Co. Plc
0.40%75.656.7%$87.94m
ICPTIntercept Pharmaceuticals, Inc.
1.86%85.6721.8%$66.06m
MNKMallinckrodt Plc
-0.93%19.2621.1%$57.13m
PTLAPortola Pharmaceuticals, Inc.
4.14%43.737.7%$53.35m
GWPHGW Pharmaceuticals PLC Sponsored ADR
0.16%151.257.6%$52.62m
CTLTCatalent Inc
-0.67%41.542.6%$52.58m
SUPNSupernus Pharmaceuticals, Inc.
-2.23%57.056.3%$41.50m
HZNPHorizon Pharma plc
0.23%17.677.5%$38.10m
UTHRUnited Therapeutics Corporation
-0.22%116.4714.4%$36.89m
AERIAerie Pharmaceuticals, Inc.
4.60%70.457.9%$35.61m

Company Profile

Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.